Kipspharma Sees 33% Surge in Revenue to 170.1 Billion Won Last Year: "Pharma-Bio Transition Pays Off" View original image

Kipsbiopharma (Kipspharma) recorded a consolidated revenue of 170.1 billion won last year, showing growth of over 30% compared to the previous year. On a separate basis, revenue increased more than sixfold, reflecting the impact of the company’s transition to the pharmaceutical and biotechnology business.


According to the Financial Supervisory Service’s electronic disclosure system on March 16, Kipspharma’s consolidated revenue for 2025 was tallied at 170.1 billion won. This represents a 33% increase from 127.6 billion won in 2024. The company has maintained growth rates in the 30% range for two consecutive years, after posting 92.1 billion won in revenue in 2023. However, last year’s operating profit was 1.6 billion won, marking a slight decrease from the previous year.


The company’s separate financial results also improved significantly. Kipspharma’s separate revenue last year was 32.6 billion won, a 552% increase from 5 billion won in the previous year. During the same period, operating profit reached 900 million won, turning profitable for the first time in four years. This growth is attributed to the full reflection of the pharmaceutical and biotechnology business results following the completion of the merger with its subsidiary, Korea Global Pharmaceutical, in the second quarter of last year.


The company is also accelerating the development of its core pipeline alongside its improved performance. The targeted anticancer drug candidate ‘Idetrexed,’ introduced from its U.S. subsidiary AlgokBio, completed its Phase 2 IND (Investigational New Drug) application with the Ministry of Food and Drug Safety on March 10. Its subsidiary, Kipsbiomed, is developing the oral peptide drug delivery platform ‘Oralloid,’ which is currently undergoing formulation optimization and preparations for overseas clinical trials.


Kipspharma is pursuing a mid- to long-term growth strategy through investment in new businesses and expansion of its distribution network. Earlier this month, the company acquired Elpispam, a cancer drug distribution specialist with annual sales of about 30 billion won, and plans to acquire shares in another pharmaceutical distributor within the year to scale up both its business size and profitability. Through these efforts, Kipspharma aims to grow into a comprehensive healthcare company encompassing pharmaceutical production, distribution, and new drug development.



Kim Hayong, Chief Executive Officer of Kipspharma, stated, “Following the merger, the pharmaceutical and biotechnology segment has rapidly taken hold, resulting in a meaningful turnaround in our performance. Based on a stable cash cow, we will accelerate the clinical advancement of our major new drug pipelines and seek to expand collaborations with global pharmaceutical companies to become a comprehensive healthcare company.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing